Glucagon-like peptide-1 therapies remain a major cost driver of employer-sponsored drug plans and will further contribute to costs as they become approved for uses beyond managing obesity and diabetes, according to a new report by Alberta Blue Cross. The report, which reviewed more than 440 new drug and supplemental submissions made to Health Canada in […]
With lyrics adapted to the tune of ‘Magic’ by Scottish pop group Pilot, the melody of ‘Oh, Oh, Oh, Ozempic’ is splashed across U.S. televisions in a snappy advertising campaign. The commercial push is likely unnecessary. Ozempic, one of the brand names of a glucagon-like peptide-1 receptor agonist medication used to treat type 2 diabetes, […]